62 related articles for article (PubMed ID: 16250369)
1. Correlation of different 5-FU regimens and time to surgery with pathological complete response in locally advanced rectal cancer patients treated by pre-operative chemo-radiation.
Chan R; Reddy M; Freeman DH
J La State Med Soc; 2005; 157(4):196-201. PubMed ID: 16250369
[TBL] [Abstract][Full Text] [Related]
2. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for anastomotic leakage after preoperative chemoradiation therapy and low anterior resection with total mesorectal excision for locally advanced rectal cancer.
Rodríguez-Ramírez SE; Uribe A; Ruiz-García EB; Labastida S; Luna-Pérez P
Rev Invest Clin; 2006; 58(3):204-10. PubMed ID: 16958295
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
Smalley SR; Benedetti JK; Williamson SK; Robertson JM; Estes NC; Maher T; Fisher B; Rich TA; Martenson JA; Kugler JW; Benson AB; Haller DG; Mayer RJ; Atkins JN; Cripps C; Pedersen J; Periman PO; Tanaka MS; Leichman CG; Macdonald JS
J Clin Oncol; 2006 Aug; 24(22):3542-7. PubMed ID: 16877719
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.
Dolinsky CM; Mahmoud NN; Mick R; Sun W; Whittington RW; Solin LJ; Haller DG; Giantonio BJ; O'Dwyer PJ; Rosato EF; Fry RD; Metz JM
J Surg Oncol; 2007 Sep; 96(3):207-12. PubMed ID: 17443718
[TBL] [Abstract][Full Text] [Related]
8. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer.
Tulchinsky H; Shmueli E; Figer A; Klausner JM; Rabau M
Ann Surg Oncol; 2008 Oct; 15(10):2661-7. PubMed ID: 18389322
[TBL] [Abstract][Full Text] [Related]
9. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Lee SH; Lee KC; Choi JH; Oh JH; Baek JH; Park SH; Shin DB
Jpn J Clin Oncol; 2008 Feb; 38(2):112-21. PubMed ID: 18263881
[TBL] [Abstract][Full Text] [Related]
10. Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
Katz MS; Minsky BD; Saltz LB; Riedel E; Chessin DB; Guillem JG
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1363-70. PubMed ID: 16029794
[TBL] [Abstract][Full Text] [Related]
11. Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
Ramani VS; Sun Myint A; Montazeri A; Wong H
Colorectal Dis; 2010 Aug; 12 Suppl 2():37-46. PubMed ID: 20618366
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemo-irradiation in un-resectable carcinoma of rectum.
Abbas A; Tunio MA; Ali N
J Ayub Med Coll Abbottabad; 2004; 16(2):24-9. PubMed ID: 15455612
[TBL] [Abstract][Full Text] [Related]
13. Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.
Urso E; Serpentini S; Pucciarelli S; De Salvo GL; Friso ML; Fabris G; Lonardi S; Ferraro B; Bruttocao A; Aschele C; Nitti D
Eur J Surg Oncol; 2006 Dec; 32(10):1201-8. PubMed ID: 16872799
[TBL] [Abstract][Full Text] [Related]
14. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant chemoradiotherapy with 5-fluorouracil by bolus.
Pasetto LM; Sinigaglia G; Basso U; Cocchio S; Compostella A; Pucciarelli S; Friso ML; Rugge M; Toppan P; Agostini M; Monfardini S
Anticancer Res; 2008; 28(6B):4095-100. PubMed ID: 19192666
[TBL] [Abstract][Full Text] [Related]
16. Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer.
Kaminski A; Joseph D; Elsaleh H
Australas Radiol; 2007 Jun; 51(3):283-8. PubMed ID: 17504322
[TBL] [Abstract][Full Text] [Related]
17. Pathologic response assessed by Mandard grade is a better prognostic factor than down staging for disease-free survival after preoperative radiochemotherapy for advanced rectal cancer.
Suárez J; Vera R; Balén E; Gómez M; Arias F; Lera JM; Herrera J; Zazpe C
Colorectal Dis; 2008 Jul; 10(6):563-8. PubMed ID: 18070184
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients.
Capirci C; Valentini V; Cionini L; De Paoli A; Rodel C; Glynne-Jones R; Coco C; Romano M; Mantello G; Palazzi S; Mattia FO; Friso ML; Genovesi D; Vidali C; Gambacorta MA; Buffoli A; Lupattelli M; Favretto MS; La Torre G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):99-107. PubMed ID: 18407433
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer.
Movsas B; Diratzouian H; Hanlon A; Cooper H; Freedman G; Konski A; Sigurdson E; Hoffman J; Meropol NJ; Weiner LM; Coia L; Lanciano R; Stein J; Kister D; Eisenberg B
Am J Clin Oncol; 2006 Oct; 29(5):435-41. PubMed ID: 17023775
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
Díaz-González JA; Calvo FA; Cortés J; García-Sabrido JL; Gómez-Espí M; Del Valle E; Muñoz-Jiménez F; Alvarez E
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1122-8. PubMed ID: 16406393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
